Cambridge's Proteostasis Slashes R&D Jobs in Focus Shift
As part of strategic restructuring, Proteostatis is laying off 46 percent of its R&D workforce, or 13 positions. Source: BioSpace
One-Time CAR-T Leader Juno Shows Off Promising New Clinical Data
The company submitted 15 abstracts to be presented at the upcoming ASH Conference. Source: BioSpace
Biogen's Early-Stage Alzheimer's Data Continues to Impress
ALZ’s researchers continue to see hope in Biogen's aducanumab. Source: BioSpace
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Ce…
Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe. Source: BioSpace
AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace
Kirin Cashes Out of Amgen Drug Joint Venture for $780M
Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen. Source: BioSpace
Daiichi Sankyo's Tumor Drug Meets Primary Endpoint in Late-Stage Study
Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint. Source: BioSpace
Bristol-Myers, Johnson & Johnson Get in on Europeon Biotech Fund's $95M Raise
The money is intended to to fuel European biotech startups. Source: BioSpace
Lundbeck Names Interim Leader, Effective Nov. 1, 2017
Anders Gotzsche will serve as interim CEO while the company looks for a replacement for Kare Schultz who leaves the company Oct. 31 for the CEO position at Teva. Source:…
Cancer Biotech Apellis Pharma Sets Terms for $150M IPO
The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15. Source: BioSpace
- Go to the previous page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- …
- 288
- Go to the next page